drug · small molecule
SAPROPTERIN DIHYDROCHLORIDE
Marketedupdated 3mo agoby $RLFTY MindMaze Therapeutics Holding SA🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for phenylketonuria and hyperphenylalaninemia and 10 investigational indications.
targets
Phenylalanine-4-hydroxylase
all catalysts(1)
Trials studying SAPROPTERIN DIHYDROCHLORIDE
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 1, 2032
~6.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- May 1, 2033patentUS 9216178*PED
- May 1, 2033patentUS 9216178*PED
- Nov 1, 2032formulationUS 9216178
- Nov 1, 2032formulationUS 9216178
- May 16, 2026patentUS 7566462*PED
- May 16, 2026patentUS 8003126*PED
- Nov 16, 2025formulationUS 7566462
- Nov 16, 2025patentUS 8003126
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that